Rigor Reviewed

Rigor-Reviewed Manuscript

Multifaceted Strategies for Hypertension Control in Low-Income Patients.

Name: Αlpha¹ Rigor Record — Multifaceted Strategies for Hypertension Control in Low-Income Patients.
Item: Multifaceted Strategies for Hypertension Control in Low-Income Patients.
Rating: 59
Author: Αlpha¹

Mills KT, Krousel-Wood M, Peacock EM, Chen J, Allouch F, Carreras AK, Geng S, Cyprian A, Davis G, Fuqua SR, Gilliam D, Greer A, Mitchell T, Gray-Winfrey W, Williams S, Wiltz GM, Winfrey KL, He H, Whelton PK, He J

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.5★ (Weak), 0 critical, 6 high issues for “Multifaceted Strategies for Hypertension Control in Low-Income Patients.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ReportingData & code availability not met−0.5★
ReportingEthical approvals partially met−0.25★
ReportingStatistical analysis partially met−0.25★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.29.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Problems surfaced7 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps3

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Ethics/consent reporting incompleteAssessed

Copyediting1

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This cluster-randomized trial is methodologically rigorous with a well-justified premise, strong design, and thorough reporting of patient characteristics and outcomes. However, it lacks a data availability statement, contains minor copyedit errors (missing minus signs in CI bounds), and overstates the scalability of the strategy. The statistics are consistent where verifiable, ethical approval is documented but regulatory compliance is not stated, and the primary p-values are reported as thresholds.

Three independent rigor evaluations were synthesized; all three agreed on the status of most dimensions. The key resources dimension was rated not applicable because the study is a behavioral/implementation trial with no investigational product. The statistics verification covered 9 tests, all consistent, but cannot verify threshold-only p-values.

6 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 9 tests: 9 consistent, 0 inconsistent; 9 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions4 pass · 2 warn · 1 fail

Prior work on hypertension prevalence and control disparities is cited, and the limitations of previous research (e.g., lack of data in FQHCs, non-randomized designs) are acknowledged. The rationale links the need for evidence-based implementation strategies in underserved populations to the study objectives. All three sub-criteria are adequately addressed.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The premise is firmly grounded in prior literature (SPRINT, prior trials, meta-analyses) with a clear rationale and identification of the evidence gap in FQHC settings.

Evidence

direct quote[Introduction, paragraphs 1-2; Discussion]

“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that intensive antihypertensive treatment targeting a systolic blood pressure <120 mm Hg significantly reduced cardiovascular disease events and all-cause mortality”